Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Ng, Oi Wing ^a   Keng, Choong Tat ^b   Leung, Cynthia Sau Wai ^c   Peiris, J S Malik ^c   Poon, Leo Lit Man ^c   Tan, Yee Joo ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; EPITOPE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VITRONECTIN; CORONAVIRUS SPIKE GLYCOPROTEIN; VIRUS ANTIBODY;

AMINO ACID SUBSTITUTION; ANTIBODY PRODUCTION; ARTICLE; CELL SURFACE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SEQUENCE; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN TARGETING; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS ENTRY; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BAT; CHEMISTRY; CHLOROCEBUS AETHIOPS; CHO CELL LINE; CRICETULUS; EPITOPE MAPPING; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PATHOGENICITY; PHYSIOLOGY; SEQUENCE ALIGNMENT; SERODIAGNOSIS; VERO CELL LINE; VIRION; VIROLOGY; VIVERRIDAE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ASPARTIC ACID; CERCOPITHECUS AETHIOPS; CHIROPTERA; CHO CELLS; CRICETULUS; EPITOPE MAPPING; HEK293 CELLS; HUMANS; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SARS VIRUS; SEQUENCE ALIGNMENT; SPIKE GLYCOPROTEIN, CORONAVIRUS; VERO CELLS; VIRION; VIVERRIDAE;

EID: 84904251567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102415     Document Type: Article

References (55)

1. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976. (Pubitemid 36569985)
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, et al. (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348: 1953-1966. (Pubitemid 36569984)
3. Peiris JS, Guan Y, Yuen KY (2004) Severe acute respiratory syndrome. Nat Med 10: S88-97. (Pubitemid 40018232)
4. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, et al. (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278. (Pubitemid 37248756)
5. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, et al. (2005) Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 102: 14040-14045. (Pubitemid 41377699)
6. Li W, Shi Z, Yu M, Ren W, Smith C, et al. (2005) Bats are natural reservoirs of SARS-like coronaviruses. Science 310: 676-679. (Pubitemid 41528160)
7. Ren W, Qu X, Li W, Han Z, Yu M, et al. (2008) Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. J Virol 82: 1899-1907. (Pubitemid 351206936)
8. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, et al. (2013) Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503: 535-538.
9. Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, et al. (2003) SARS-beginning to understand a new virus. Nat Rev Microbiol 1: 209-218.
10. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, et al. (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300: 1394-1399. (Pubitemid 36638152)
11. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, et al. (2003) The Genome sequence of the SARS-associated coronavirus. Science 300: 1399-1404. (Pubitemid 36638153)
12. Li W, Wong SK, Li F, Kuhn JH, Huang IC, et al. (2006) Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol 80: 4211-4219.
13. Wong SK, Li W, Moore MJ, Choe H, Farzan M (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279: 3197-3201. (Pubitemid 38140552)
14. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS (2003) The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 312: 1159-1164. (Pubitemid 37490937)
15. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450-454. (Pubitemid 37490132)
16. Tripet B, Howard MW, Jobling M, Holmes RK, Holmes KV, et al. (2004) Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem 279: 20836-20849. (Pubitemid 38656480)
17. Xu Y, Zhu J, Liu Y, Lou Z, Yuan F, et al. (2004) Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry 43: 14064-14071. (Pubitemid 39482756)
18. Sainz B Jr, Rausch JM, Gallaher WR, Garry RF, Wimley WC (2005) Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. J Virol 79: 7195-7206. (Pubitemid 40677349)
19. Xu Y, Lou Z, Liu Y, Pang H, Tien P, et al. (2004) Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 279: 49414-49419. (Pubitemid 39625827)
20. Hofmann H, Pohlmann S (2004) Cellular entry of the SARS coronavirus. Trends Microbiol 12: 466-472. (Pubitemid 39286125)
21. McReynolds S, Jiang S, Guo Y, Celigoy J, Schar C, et al. (2008) Characterization of the prefusion and transition states of severe acute respiratory syndrome coronavirus S2-HR2. Biochemistry 47: 6802-6808. (Pubitemid 351898935)
22. He Y, Zhou Y, Liu S, Kou Z, Li W, et al. (2004) Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochemical and Biophysical Research Communications 324: 773-781. (Pubitemid 39345582)
23. Du L, He Y, Zhou Y, Liu S, Zheng BJ, et al. (2009) The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 7: 226-236.
24. Yeung KS, Yamanaka GA, Meanwell NA (2006) Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Med Res Rev 26: 414-433. (Pubitemid 43939201)
25. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10: 871-875. (Pubitemid 39070862)
26. Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, et al. (2005) Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J Virol Methods 128: 21-28. (Pubitemid 40980205)
27. Tsunetsugu-Yokota Y, Ohnishi K, Takemori T (2006) Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine. Rev Med Virol 16: 117-131.
28. Coughlin MM, Prabhakar BS (2012) Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol 22: 2-17.
29. Spiga O, Bernini A, Ciutti A, Chiellini S, Menciassi N, et al. (2003) Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem Biophys Res Commun 310: 78-83. (Pubitemid 37162765)
30. Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS (2012) Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One 7: e50366.
31. Lip KM, Shen S, Yang X, Keng CT, Zhang A, et al. (2006) Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J Virol 80: 941-950. (Pubitemid 43062906)
32. Keng CT, Zhang A, Shen S, Lip KM, Fielding BC, et al. (2005) Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J Virol 79: 3289-3296. (Pubitemid 40327918)
33. Garcia JM, Lai JC (2011) Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update. Expert Rev Anti Infect Ther 9: 443-455.
34. Giroglou T, Cinatl J Jr, Rabenau H, Drosten C, Schwalbe H, et al. (2004) Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol 78: 9007-9015. (Pubitemid 39096512)
35. Moore MJ, Dorfman T, Li W, Wong SK, Li Y, et al. (2004) Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol 78: 10628-10635. (Pubitemid 39258389)
36. Hofmann H, Hattermann K, Marzi A, Gramberg T, Geier M, et al. (2004) S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 78: 6134-6142. (Pubitemid 38715911)
37. Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, et al. (2005) Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 11: 411-416. (Pubitemid 40315726)
38. Sui J, Li W, Roberts A, Matthews LJ, Murakami A, et al. (2005) Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 79: 5900-5906. (Pubitemid 40617195)
39. He Y, Li J, Li W, Lustigman S, Farzan M, et al. (2006) Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 176: 6085-6092.
40. Duan J, Yan X, Guo X, Cao W, Han W, et al. (2005) A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun 333: 186-193. (Pubitemid 40813463)
41. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, et al. (2008) A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26: 6338-6343.
42. Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, et al. (2007) Evolutionary insights into the ecology of coronaviruses. J Virol 81: 4012-4020. (Pubitemid 46586896)
43. Graham RL, Baric RS (2010) Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol 84: 3134-3146.
44. Shi Z, Hu Z (2008) A review of studies on animal reservoirs of the SARS coronavirus. Virus Res 133: 74-87. (Pubitemid 351374754)
45. Dimitrov DS (2004) Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2: 109-122.
46. Coughlin MM, Babcook J, Prabhakar BS (2009) Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology 394: 39-46.
47. Miyoshi-Akiyama T, Ishida I, Fukushi M, Yamaguchi K, Matsuoka Y, et al. (2011) Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. J Infect Dis 203: 1574-1581.
48. Zhong X, Yang H, Guo ZF, Sin WY, Chen W, et al. (2005) B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J Virol 79: 3401-3408. (Pubitemid 40327928)
49. Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth D, et al. (2010) Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol 84: 11336-11349.
50. Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, et al. (2008) Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol 82: 3220-3235. (Pubitemid 351429902)
51. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, et al. (2007) Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 104: 12123-12128. (Pubitemid 47185640)
52. Mitsuki YY, Ohnishi K, Takagi H, Oshima M, Yamamoto T, et al. (2008) A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV. Microbes Infect 10: 908-915.
53. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77: 8801-8811. (Pubitemid 36936092)
54. Chakraborti S, Prabakaran P, Xiao X, Dimitrov DS (2005) The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2: 73.
55. Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, et al. (2006) Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Res 120: 146-155. (Pubitemid 43947310)